Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vir Biotechnology's share price for the quarter that ended in Jun. 2026 was MXN170. Vir Biotechnology's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 169 Mil. Therefore, Vir Biotechnology's market cap for the quarter that ended in Jun. 2026 was MXN28,762 Mil.
Vir Biotechnology's quarterly market cap
increased
from Dec. 2025 (MXN23,990 Mil) to Mar. 2026 (MXN27,410 Mil) and
increased
from Mar. 2026 (MXN27,410 Mil) to Jun. 2026 (MXN28,762 Mil).
Vir Biotechnology's annual market cap
increased
from Dec. 2023 (MXN23,182 Mil) to Dec. 2024 (MXN23,557 Mil) and
increased
from Dec. 2024 (MXN23,557 Mil) to Dec. 2025 (MXN23,990 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vir Biotechnology's Enterprise Value for Today is MXN19,900 Mil.
Vir Biotechnology (MEX:VIR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vir Biotechnology Market Cap Related Terms
Vir Biotechnology Market Cap Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VIR vs AVBP, XNCR, SEPN: Market Cap Comparison
For the Biotechnology subindustry, Vir Biotechnology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Market Cap distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vir Biotechnology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (MEX:VIR) has a Market Cap of MXN27,386 Mil as of Aug. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #221 out of 1422 companies in the Biotechnology industry, placing it in the top 15.5%.
Is Vir Biotechnology's Market Cap too high?
Vir Biotechnology's current Market Cap is MXN27,386 Mil. Based on the distribution chart, Vir Biotechnology ranks #221 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Market Cap compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #221 out of 1422 companies for Market Cap. This places Vir Biotechnology in the top 16% of its industry — outperforming the majority of peers. The industry median Market Cap is 118.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.87, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vir Biotechnology and its competitors. For the Biotechnology industry, the median Market Cap is 118.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vir Biotechnology's current Market Cap is MXN27,386 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Market Cap of MXN27,386 Mil. The stock's GF Value™ is MXN764.28, compared to a current price of MXN170.00 — trading 77.8% below its estimated fair value. The current Market Cap is MXN27,386 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Market Cap is MXN27,386 Mil as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.8% below its estimated GF Value™ of MXN764.28.
Key valuation signals for MEX:VIR:
Market Cap: MXN27,386 Mil
GF Value™: MXN764.28 vs. price of MXN170.00 (77.8% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
